Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Payables (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Payables for 4 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables fell 52.57% to $5.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.0 million, a 52.57% decrease, with the full-year FY2025 number at $5.0 million, down 52.57% from a year prior.
  • Payables was $5.0 million for Q4 2025 at Phathom Pharmaceuticals, up from $1.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $12.6 million in Q4 2023 to a low of $1.1 million in Q3 2025.
  • A 4-year average of $6.8 million and a median of $6.5 million in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: soared 83.42% in 2024, then tumbled 84.93% in 2025.
  • Phathom Pharmaceuticals' Payables stood at $10.0 million in 2022, then grew by 26.05% to $12.6 million in 2023, then fell by 16.62% to $10.5 million in 2024, then tumbled by 52.57% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Payables are $5.0 million (Q4 2025), $1.1 million (Q3 2025), and $4.0 million (Q2 2025).